Sector: MedicalNovartis AG (NYSE: NVS)
Ranking History
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 264 |
Technical : | 73 |
Performance : | 185 |
Overall: | 206 |
Number of Stocks: | 306 |
Scan Date: | 10/20/2009 |
Sector: | Medical |
Funamental : | 262 |
Technical : | 122 |
Performance : | 198 |
Overall: | 240 |
Number of Stocks: | 305 |
Scan Date: | 10/15/2009 |
Sector: | Medical |
Funamental : | 263 |
Technical : | 82 |
Performance : | 208 |
Overall: | 221 |
Number of Stocks: | 305 |
Headlines
- The Week in Review: Major Investments
Nov 07, 2009 09:38 PM | NVS, SVA
- Hamilton Thorne files second quarter results as part of qualifying transaction requirements
Nov 06, 2009 04:16 PM | CRL, DD, MON, MRK, NVS
- Confederation of Indian Industry and U.S.-India Business Council Announce Healthcare Partnership
Nov 05, 2009 11:30 PM | NVS
- Novartis gets green light for cell culture-based A/H1N1 flu vaccine
Nov 05, 2009 04:27 PM | NVS
- NOVARTIS EXPANDS INTO CHINESE PHARMACEUTICAL MARKET
Nov 05, 2009 01:25 PM | NVS
- NeuroVive: NeuroVive doses last patient in clinical trial of cremophor(R)- free cyclosporine i.v. NeuroSTAT(R)
Nov 05, 2009 03:07 AM | NVS
- Novartis receives regulatory approval in Germany for Celtura®, a cell
culture-based Influenza A(H1N1) pandemic vaccine
Nov 05, 2009 01:16 AM | NVS
- MIT Enterprise Forum of Cambridge Presents "Vaccines and Global Health: New Technologies Create Global Opportunities"
Nov 04, 2009 03:40 PM | NVS
- NOVARTIS TO INVEST USD1B TO ESTABLISH THE GLOBAL THIRD LARGEST R&D CENTER
Nov 04, 2009 01:25 PM | NVS
- Opexa Therapeutics Reports Third Quarter 2009 Financial Results and Corporate Update
Nov 04, 2009 08:33 AM | NVS, OPXA
- QLT Announces Third Quarter Results for 2009
Oct 27, 2009 07:53 AM | NVS, QLTI
- UPI NewsTrack TopNews
Oct 24, 2009 01:17 PM | NVS
- UPI NewsTrack TopNews
Oct 24, 2009 08:34 AM | NVS
- CDC: 16 million flu vaccine doses shipped
Oct 24, 2009 08:12 AM | NVS
- UPI NewsTrack Health and Science News
Sep 15, 2009 05:51 PM | NVS
- FDA approves four H1N1 vaccines
Sep 15, 2009 03:55 PM | NVS
- One-dose H1N1 vaccine may be on the way
Sep 04, 2009 12:27 AM | NVS
- Canada studies asthma drug Xolair risks
Aug 13, 2009 12:37 PM | NVS
- Alcon Profit Rises 2.6% in Second Quarter
Jul 23, 2009 02:13 AM | ACL, AZN, NSRGY, NVS
- Scientists solve a drug shelf-life problem
Jul 08, 2009 04:38 PM | NVS
- Bernhard Hampl, Ph.D. Elected to Serve As Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.
Nov 03, 2009 12:52 AM | NVS
- RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on PCP, NVS, SPR, MUR, PG and OSK
Oct 27, 2009 07:15 AM | MUR, NVS, OSK, PCP, PG, SPR
- Novus Energy Inc. grants performance warrants and options
Sep 04, 2009 01:08 PM | NVS
- Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
Aug 26, 2009 09:51 AM | NVS
- Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes
Aug 26, 2009 07:55 AM | NVS
- Novus Energy Inc. announces third quarter 2009 results
Aug 25, 2009 06:02 PM | NVS
- Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
Aug 25, 2009 11:50 AM | NVS
- BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Aug 06, 2009 06:53 AM | ARNA, AVII, AZN, BMR, CEPH, EPCT
- Standard & Poor's annonce des modifications a l'indice compose S&P/TSX de croissance
Aug 04, 2009 05:42 PM | NVS, REG
- Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
Jul 30, 2009 10:51 AM | ENDP, NVS
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
NVS
|
Compare to S&P
|
| YTD |
4.40 %
|
-8.99 %
|
| 4 Weeks |
4.76 %
|
3.65 %
|
| 12 Weeks |
16.01 %
|
13.13 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 3.37 %
|
|
EPS Growth in Last Year: 0.00 %
|
|
Sales Growth in Last Quarter: 3.20 %
|
|
Sales Growth in Last Quarter: 3.15 %
|
|
